Reblozyl® (luspatercept-aamt) – Expanded indication
August 28, 2023 - Bristol Myers Squibb announced the FDA approval of Reblozyl (luspatercept-aamt), for the treatment of anemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions.
Top